Contact Us    Downloads    Login  
   
              
 

Case Studies

The Sage Group has engaged with many companies over the last 15 years, representing the company and/or their stakeholders to maximise value. Please click on any examples in the box on the right to access details of some representative transactions, in order to see how we have worked successfully with our valued clients. If you would like more information please contact us.

Microdose Technologies

  • Sage invested over $200,000 in MicroDose at $1 per share as part of a financing in excess of $750,000 arranged by Sage.
  • Sage assisted in negotiating a $30 million marketing partnership with BMS for a joint ventur...

    View case study

McKinley
Date: 01 Jul 2007

  • McKinley was part of Broe Companies Inc
  • Sage engaged with McKinley Medical's management to sell its Walkmed drug infusion business as part of a corporate divestiture program
  • WalkMed Infusion LLC was...

    View case study

iStat Corporation

  • Served as first President and CEO
  • Developed chemical biosensors in the medical technology space for blood gases and analytes
  • Developed commercialisation and funding strategies for the company over s...

    View case study

Cenix

  • Engaged with RNAi biotech company at invitation of principal shareholders
  • Developed IM and divestment strategy to realise exit for investors
  • Divested primary technology platform to Ambion, who were ...

    View case study

NitroMed

  • Sold non-relevant patent right Ohmeda for $1 million within 90 days of getting assignment
  • Internal investors heartened to bridge additional funds
  • Completed two licensing transactions with J&J co...

    View case study

Focal

  • Engaged with the company to advise on marketing and regulatory hurdles to develop polymer bioadhesive medical technology as a lung sealant
  • Prepared a detailed valuation model which led to business plan and inform...

    View case study

Luminex

  • Sage worked with this imaging/diagnostics company from a startup with 3 employees in a garage
  • Sage wrote the company’s first business plan and investment memorandum for a novel diagnostics business
    • ...

    View case study

SK BioPharmaceuticals

  • Small US biopharm subsidiary of SK Corporation of Korea seeking to out-license an anti-epileptic and anti-depressant in early clinical trials
  • Little or no experience with multi-national pharma
  • Sage ...

    View case study

RGene Therapeutics

  • Sage assisted in negotiating a $1 million patent license with Pasteur Merieux Connaught
  • Sage assisted in negotiating a $30 million European marketing partnership with Fournier
  • As a result of these t...

    View case study

NatImmune

  • Tired investors desiring a partnership of the lead protein replacement technology before further supporting the company
  • Sage engaged Enzon as well as three other parties
  • Closed a deal with $10 mil. ...

    View case study

Life Science Resources

  • Assisted in founding of company involved in photonics and biological imaging for high throughput drug discovery and proteomics
  • Assisted in fund raising and technology/IP development
  • Developed high p...

    View case study

Noven

  • Noven, a specialty neuro pharma company, engaged Sage to assist it in a buyside transaction
  • Objectives were specified as increasing revenue, requirement for an expanded sales infrastructure and enhanced product p...

    View case study

Cytomyx

  • Biotech drug discovery company quoted on AIM market of the London Stock Exchange
  • Board sought to divest company to realize cash return in light of depressed market capitalisation
  • Sage identified Ser...

    View case study

Biotrin

  • Requested by Board and VC investors to engineer an exit route from this Dublin-based clinical diagnostics company
  • Assisted company to increase US-based market share
  • Developed IM and identified sever...

    View case study


Tel-Aviv, Israel, March 27, 2013 - Sage's client RedHill Biopharma Ltd. (NASDAQ: RDHL; TASE: RDHL) (the “Company” or “RedHill”), an emerging Israeli biopharmaceutical company focused primar...Read entire article



The Sage Group is pleased to announce that Wayne Pambianchi, Executive Director, gave an invited lecture to entrepreneurs at a European conference in Warsaw in February 2013. The video can be viewed on YouTube using the link belo...Read entire article



Barcelona, Spain – Feb 2013 – The Sage Group (www.sagehealthcare.com)  is pleased to announce its appointment by Palau Pharma S.A. as advisors to develop strategic corporat...Read entire article

Contact Us

If you are interested in contacting us or obtaining the contact details for one of our offices, please use our contact page.

If you would like to make a more comprehensive business enquiry, you can send us further details of your company using our Business Enquiry Form.
© The Sage Group 2008 Site by YouSoft   Privacy Policy   Contact us